THE SCREENING PROJECT

The first project of the Check@Home consortium is a pilot population screening program which aims to develop a program for the early detection of cardiovascular disease, chronic kidney disease and type 2 diabetes in three Dutch regions (Breda, Utrecht, and Arnhem). The screening infrastructure will be developed through a phased implementation and iterative design in the four regions. This approach enables adaptation and refinement of the screening based on new technologies, lessons learned, and the preferences of end-users and other stakeholders. When finalizing the screeining project, the effectiveness and cost-effectiveness of the screening will be assessed, with all activities conducted in collaboration with relevant stakeholders.

 

A random sample of 160,000 individuals aged 50 to 75 living in one of the three selected regions will be invited to participate in the Check@Home screening program. The screening consists of three phases, explained in more detail below. A second random sample of 160,000 individuals will be used for future comparisons of events and hospital admissions between screened and unscreened populations. This screening project is possible due to a grant from the Dutch Research Council (NWO, grant nr. KICH2.V4C.20.005) and financial contributions from the Dutch Heart Foundation, the Dutch Kidney Foundation, the Dutch Diabetes Research Foundation, and various private partners, including Roche Diagnostics, AstraZeneca, Siemens Healthineers, Topicus, and Happitech.
READ MORE

RESEARCH METHOD EXPLAINED

1. Home-based screening phase

All subjects will receive the invitation via mail, including information and instructions to download an app onto their smartphones. The app will enable participants to carry out the home-based tests, including the heart rhythm test to check for the heart rhythm disorder atrial fibrillation. Participants are also instructed to collect a urine sample and send this sample via the mail to the laboratory for the analyses of albuminuria, as indicator of chronic kidney disease. In addition, a subset of participants will be asked to complete a short questionnaire via the app.

2. Diagnostic phase

All participants with a positive home-based screening test will be invited for a detailed follow-up examination at a regional diagnostic center to identify cardiovascular diseases, chronic kidney disease, type 2 diabetes, and their risk factors. The diagnostic procedures will include physical measurements (such as anthropometrics and blood pressure), blood tests (including lipid profile, glucose, HbA1c, creatinine, and NT-proBNP), urine tests (albumin-to-creatinine ratio), an ECG, and a questionnaire.

3. Care phase

Participants with abnormalities detected during the diagnostic screening will be referred to their general practitioners for appropriate care, including lifestyle advice and/or medication. To address the low participation in the care phase observed in previous studies and to alleviate the burden on primary care, an alternative care pathway will also be assessed. In this pathway, participants will receive treatment at a regional treatment facility as part of the screening process.

The Check@Home study design.

Home-based screening tests

Several home-based screening tests will be implemented in the screening program. In the first region, region Breda, we will start with the following tests:

  • For the urine test, the CE-certified PeeSpot urine collection device will be used. The PeeSpot includes a tube containing a holder with an absorbent pad that can absorb up to 1.3 ml of urine. Participants can easily collect a urine sample at home by urinating over the pad. The tube, along with the holder and pad, can then be mailed to the laboratory for measuring albuminuria (albumin-to-creatinine ratio), an early marker of chronic kidney disease.
  • Participants can detect the heart rhythm disorder atrial fibrillation using the heart rhythm test within the app, which includes the CE-certified Happitech software. This software relies on photoplethysmographic signals to assess heart rhythm.
  • A subset of participants will receive a questionnaire that includes the RED-CVD tool, designed to identify individuals with atrial fibrillation, coronary artery disease, and heart failure, as well as questions aimed at the early detection of type 2 diabetes and questions regarding the assessment of the participants' health literacy. The questionnaire will first be implemented in Breda in a small subset, where its effectiveness will be assessed based on participation rates, score distribution, and overlap with disease presence. The insights gained will guide the screening process in subsequent regions.

 

The PeeSpot urine collection device.

Standard strategy versus alternative strategies

In the three phases of the study, a distinction is made between standard screening strategies and alternative strategies. Standard screening strategies include established techniques that can be implemented in practice based on previous research, while the alternative strategies involve more innovative methods that, for example, still need to be developed or validated in a specific population, which will occur as part of the project.

© 2024 Oscar Prent Assurantiën BV 
© 2026 Check@Home
Design and realisation by:
Design and realisation by: